ArticlePloS one2023

Lack of effectiveness of Bebtelovimab monoclonal antibody among high-risk patients with SARS-Cov-2 Omicron during BA.2, BA.2.12.1 and BA.5 subvariants dominated era.

Srilekha Sridhara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.